Andrology, Sexology & STIs Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Sex Med Rev. 2021 Jan;9(1):15-22. doi: 10.1016/j.sxmr.2020.08.006. Epub 2020 Sep 8.
The recent global outbreak of coronavirus disease 2019 (COVID-19) has become a pandemic with a lot of sufferers. Excessive inflammation, exaggerated immune response, with ultimate apoptosis contribute to COVID-19 pathology that progress to acute lung acute respiratory distress.
To shed a light on the likely benefits of the oral phosphodiesterase 5 (PDE5) inhibitor adjuvant role in combating COVID-19 infection.
A literature review was performed in the PubMed/Medline database, Scopus, Cochrane Library, EMBASE, Academic Search Complete, Google Scholar, and CINAHL databases using the keywords COVID-19; phosphodiesterase-5 inhibitors; cytokine storm; respiratory distress.
Despite the worsening trends of COVID-19, still no drugs are validated to have significant clinical efficacy in the treatment of patients with COVID-19 in large-scale studies. While the progress toward a curative agent and/or vaccine is certainly hopeful, the principal limiting factor in such public health emergencies is always the time. Therefore, a preexisting licensed therapeutic(s) might offer a reprieve to the healthcare systems operating at the edge of capacity. In this context, the innovation of oral PDE5 inhibitors with their valuable effects on erection have provided a breakthrough in the treatment of erectile dysfunction and opened new fields of clinical application for this class of drugs. Oral PDE5 inhibitors have been demonstrated to possess many beneficial useful additional implications with acknowledged anti-inflammatory, antioxidant, immune response regulation, and antiapoptotic properties. These properties have been elucidated through the nitric oxide/soluble guanylyl cyclase/cyclic guanylate monophosphate pathway in addition to the emerged hemeoxygenase-1 enzyme as well as hydrogen sulfide pathways. These properties could support repurposing oral PDE5 inhibitors' potential adjuvant use in targeting different aspects of COVID-19 infection.
Oral PDE5 inhibitors retain several acknowledged off-labeled useful implications with anti-inflammatory, antioxidant, immune response regulation, and antiapoptotic properties. These properties may support repurposing oral PDE5 inhibitors' potential adjuvant use in the protocols combating COVID-19 manifestations. Mostafa T. Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating Coronavirus Disease 2019 Infection? Sex Med Rev 2021;9:15-22.
最近全球爆发的 2019 年冠状病毒病（COVID-19）已成为一种大流行疾病，有大量患者。过度的炎症、免疫反应过度，最终导致细胞凋亡，导致 COVID-19 病理学进展为急性肺急性呼吸窘迫。
探讨口服磷酸二酯酶 5（PDE5）抑制剂辅助治疗 COVID-19 感染的可能益处。
在 PubMed/Medline 数据库、Scopus、Cochrane 图书馆、EMBASE、Academic Search Complete、Google Scholar 和 CINAHL 数据库中使用 COVID-19、磷酸二酯酶-5 抑制剂、细胞因子风暴、呼吸窘迫等关键词进行文献回顾。
尽管 COVID-19 的趋势恶化，但在大规模研究中，仍没有药物被证实对 COVID-19 患者的治疗具有显著的临床疗效。虽然治疗药物和/或疫苗的研发进展令人充满希望，但在这种公共卫生紧急情况下，主要的限制因素始终是时间。因此，现有的已批准的治疗药物可能为处于能力边缘的医疗系统提供缓解。在这种情况下，具有治疗勃起功能障碍突破性作用的口服 PDE5 抑制剂的创新为该类药物的临床应用开辟了新的领域。已经证明，口服 PDE5 抑制剂具有许多有益的额外作用，具有抗炎、抗氧化、免疫反应调节和抗凋亡特性。这些特性通过一氧化氮/可溶性鸟苷酸环化酶/环鸟苷单磷酸途径以及新出现的血红素加氧酶-1 酶和硫化氢途径得到了阐明。这些特性可能支持重新利用口服 PDE5 抑制剂在靶向 COVID-19 感染的不同方面的潜在辅助用途。
口服 PDE5 抑制剂具有抗炎、抗氧化、免疫反应调节和抗凋亡等公认的非标签用途。这些特性可能支持重新利用口服 PDE5 抑制剂在对抗 COVID-19 表现的方案中的潜在辅助用途。Mostafa T. 口服磷酸二酯酶 5 抑制剂在对抗 2019 年冠状病毒病感染方面可能具有辅助作用吗？性医学评论 2021；9:15-22。
